A. Matsuhisa

发表

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

S. Hatakeyama, M. Sasamata, K. Yamanaka, 2011, Anti-cancer drugs.

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin

Shigeki Kawabata, M. Sasamata, K. Furuichi, 2012, Molecular & Cellular Proteomics.

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Shigeki Kawabata, M. Sasamata, M. Kobori, 2012, Biochemical and biophysical research communications.

Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine.

T. Shibanuma, Y. Matsumoto, H. Nohira, 2000, Bioorganic & medicinal chemistry.

Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.

A. Tanaka, Y. Shimada, T. Yatsu, 2000, Chemical & pharmaceutical bulletin.

Novel potassium channel activators: synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives.

Y. Matsumoto, W. Uchida, M. Asano, 1996, Chemical & pharmaceutical bulletin.

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.

H. Koshio, A. Tanaka, T. Yatsu, 1997, Chemical & pharmaceutical bulletin.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives.

T. Suzuki, T. Furuya, K. Miyata, 1996, Chemical & pharmaceutical bulletin.

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.

H. Koshio, A. Tanaka, T. Yatsu, 2000, Chemical & pharmaceutical bulletin.

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

S. Hatakeyama, M. Sasamata, K. Yamanaka, 2007, Cancer research.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. II. Synthesis and structure-activity relationships of 4,5,6,7-tetrahydro-1H-benzimidazole derivatives.

T. Suzuki, T. Furuya, K. Miyata, 1996, Chemical & pharmaceutical bulletin.

YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation.

S. Kuromitsu, M. Shibasaki, M. Yamano, 2006, Cancer letters.

Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

M. Sasamata, K. Yamanaka, T. Nakahara, 2011, Cancer science.

YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors

H. Hisamichi, S. Kuromitsu, M. Shibasaki, 2006, Clinical Cancer Research.

YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.

S. Kuromitsu, M. Shibasaki, M. Yamano, 2005, Biological & pharmaceutical bulletin.

New water-soluble fluorogenic amine. 7-Aminocoumarin-4-methanesulfonic acid (ACMS) and related substrates for proteinases.

Y. Kanaoka, A. Matsuhisa, E. Sato, 1988, Chemical & pharmaceutical bulletin.

Novel 5-Hydroxytryptamine (5-HT3) Receptor Antagonists. Synthesis and Structure-Activity Relationships of 9-Methyl-2,3,4,9- tetrahydrothiopyrano(2,3-b)indol-4-one Derivatives.

K. Miyata, M. Ohta, Takeshi Suzuki, 1997 .

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. Synthesis and structure-activity relationships of 9-methyl-2,3,4,9-tetrahydrothiopyrano[2,3-b]indol-4-one derivatives.

T. Suzuki, K. Miyata, M. Ohta, 1997, Chemical & pharmaceutical bulletin.

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

M. Orita, J. Tsukada, A. Kakefuda, 2006, Bioorganic & medicinal chemistry.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

J. Tsukada, A. Tanaka, Y. Shimada, 2005, Chemical & pharmaceutical bulletin.

Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.

A. Tanaka, Y. Shimada, A. Tahara, 2003, Chemical & pharmaceutical bulletin.

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

S. Hatakeyama, M. Sasamata, K. Yamanaka, 2011, Anti-cancer drugs.

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives.

H. Koshio, A. Tanaka, T. Yatsu, 1997, Chemical & pharmaceutical bulletin.